The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.
Open accessAbstract
The posttranslational addition of a farnesyl moiety to the Ras oncoprotein is essential for its transforming activity. Cell-active inhibitors of the enzyme that catalyzes this reaction, protein farnesyltransferase, have been shown to selectively block ras-dependent transformation of cells in culture. Here we describe the protein farnesyltransferase inhibitor 2(S)-[2(S)-[2(R)-amino-3-mercapto]propylamino-3(S)-methyl] pentyloxy-3-phenylpropionylmethioninesulfone methyl ester (L-739,749), which suppressed the anchorage-independent growth of Rat1 cells transformed with viral H-ras and the human pancreatic adenocarcinoma cell line PSN-1, which harbors altered K-ras, myc, and p53 genes. This compound also suppressed the growth of tumors arising from ras-transformed Rat1 cells in nude mice by 66%. Under the same conditions, doxorubicin inhibited tumor growth by 33%. Control tumors formed by v-raf- or v-mos-transformed Rat1 cells were unaffected by L-739,749. Furthermore, mice treated with L-739,749 exhibited no evidence of systemic toxicity. This is a demonstration of antitumor activity in vivo using a synthetic small molecule inhibitor of protein farnesyltransferase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
All ras proteins are polyisoprenylated but only some are palmitoylated
Hancock, J. F., Magee, A. I., Childs, J. E., & Marshall, C. J. (1989) · Cell · doi:10.1016/0092-8674(89)90054-8 · Cited by 1,799
p21ras is modified by a farnesyl isoprenoid.
Casey, P. J., Solski, P. A., Der, C. J., & Buss, J. E. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.21.8323 · Cited by 856
Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides
Reiss, Y., Goldstein, J. L., Seabra, M. C., Casey, P. J., & Brown, M. S. (1990) · Cell · doi:10.1016/0092-8674(90)90242-7 · Cited by 817
Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP.
Feig, L. A., & Cooper, G. M. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.8.3235 · Cited by 798
Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation In Animal Cells
James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDowell, R. S., Crowley, C. W., Lucas, B. K., Levinson, A. D., & Marsters, J. C. (1993) · Science · doi:10.1126/science.8316834 · Cited by 630
Requirement for c-ras proteins during viral oncogene transformation
Smith, M. R., DeGudicibus, S. J., & Stacey, D. W. (1986) · Nature · doi:10.1038/320540a0 · Cited by 621
Altered Growth of Human Colon Cancer Cell Lines Disrupted at Activated Ki- ras
Shirasawa, S., Furuse, M., Yokoyama, N., & Sasazuki, T. (1993) · Science · doi:10.1126/science.8465203 · Cited by 620
Sequence dependence of protein isoprenylation
Moores, S. L., Schaber, M. D., Mosser, S. D., Rands, E., O'Hara, M. B., Garsky, V. M., Marshall, M. S., Pompliano, D. L., & Gibbs, J. B. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98729-6 · Cited by 580
Self-citationSelective Inhibition of ras -Dependent Transformation by a Farnesyltransferase Inhibitor
Kohl, N. E., Mosser, S. D., deSolms, S. J., Giuliani, E. A., Pompliano, D. L., Graham, S. L., Smith, R. L., Scolnick, E. M., Oliff, A., & Gibbs, J. B. (1993) · Science · doi:10.1126/science.8316833 · Cited by 579
Self-citationBiological and biochemical properties of human rasH genes mutated at codon 61
Der, C. J., Finkel, T., & Cooper, G. M. (1986) · Cell · doi:10.1016/0092-8674(86)90495-2 · Cited by 543
Kato, K., Cox, A. D., Hisaka, M. M., Graham, S. M., Buss, J. E., & Der, C. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.14.6403 · Cited by 540
Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic
Gibbs, J. B., Oliff, A., & Kohl, N. E. (1994) · Cell · doi:10.1016/0092-8674(94)90308-5 · Cited by 517
Self-citationRas C-terminal processing enzymes—New drug targets?
Gibbs, J. B. (1991) · Cell · doi:10.1016/0092-8674(91)90352-y · Cited by 454
Willumsen, B. M., Norris, K., Papageorge, A. G., Hubbert, N. L., & Lowy, D. R. (1984) · The EMBO Journal · doi:10.1002/j.1460-2075.1984.tb02177.x · Cited by 399
Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation.
Jackson, J. H., Cochrane, C. G., Bourne, J. R., Solski, P. A., Buss, J. E., & Der, C. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.8.3042 · Cited by 338
Identification of Ras farnesyltransferase inhibitors by microbial screening.
Hara, M., Akasaka, K., Akinaga, S., Okabe, M., Nakano, H., Gomez, R., Wood, D., Uh, M., & Tamanoi, F. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.6.2281 · Cited by 257
Self-citationPolyisoprenylation of Ras in vitro by a farnesyl-protein transferase.
Schaber, M. D., O'Hara, M. B., Garsky, V. M., Mosser, S. C., Bergstrom, J. D., Moores, S. L., Marshall, M. S., Friedman, P. A., Dixon, R. A., & Gibbs, J. B. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)77164-0 · Cited by 227
Self-citationPeptidomimetic inhibitors of Ras farnesylation and function in whole cells.
Garcia, A. M., Rowell, C., Ackermann, K., Kowalczyk, J. J., & Lewis, M. D. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)46638-5 · Cited by 220
Prendergast, G. C., Davide, J. P., deSolms, S. J., Giuliani, E. A., Graham, S. L., Gibbs, J. B., Oliff, A., & Kohl, N. E. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.6.4193 · Cited by 209
Self-citationLimonene-induced regression of mammary carcinomas.
Haag, J. D., Lindstrom, M. J., & Gould, M. N. (1992) · PubMed · Cited by 209
Kitten, G. T., & Nigg, E. A. (1991) · The Journal of cell biology · doi:10.1083/jcb.113.1.13 · Cited by 196
Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein.
Cox, A. D., Hisaka, M. M., Buss, J. E., & Der, C. J. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.6.2606 · Cited by 178
Omer, C. A., Kral, A. M., Diehl, R. E., Prendergast, G. C., Powers, S., Allen, C. M., Gibbs, W. W., & Kohl, N. E. (1993) · Biochemistry · doi:10.1021/bi00070a028 · Cited by 138
Self-citationras -Induced Neuronal Differentiation of PC12 Cells: Possible Involvement of fos and jun
Sassone‐Corsi, P., Der, C. J., & Verma, I. M. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.8.3174 · Cited by 132
Trueblood, C. E., Ohya, Y., & Rine, J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.7.4260-4275.1993 · Cited by 123
Nigam, M., Seong, C. M., Qian, Y., Hamilton, A. D., & Sebti, S. M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36832-2 · Cited by 114
Sebti, S. M., Tkalcevic, G. T., & Jani, J. P. (1991) · Cancer Communications · doi:10.3727/095535491820873371 · Cited by 104
cDNA cloning and expression of rat and human protein geranylgeranyltransferase type-I.
Zhang, F. L., Diehl, R. E., Kohl, N. E., Gibbs, W. W., Giros, B., Casey, P. J., & Omer, C. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41845-x · Cited by 94
Self-citationCaplin, B. E., Hettich, L., & Marshall, M. S. (1994) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/0167-4838(94)90089-2 · Cited by 77
The ras/cholesterol connection: implications for ras oncogenicity.
Cox, A. D., & Der, C. J. (1992) · PubMed · Cited by 77
Yamada, H., Yoshida, T., Sakamoto, H., Terada, M., & Sügimura, T. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(86)91072-7 · Cited by 74
Cited by
Differentiation and reversal of malignant changes in colon cancer through PPARγ
Sarraf, P., Mueller, E., Jones, D., King, F. J., DeAngelo, D. J., Partridge, J. B., Holden, S. A., Chen, L. B., Singer, S., Fletcher, C., et al. (1998) · Nature Medicine · doi:10.1038/2030 · Cited by 988
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Dhanasekaran, R., Deutzmann, A., Mahauad-Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00549-2 · Cited by 986
Ras in Cancer and Developmental Diseases
Fernandez-Medarde, A., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911411084 · Cited by 897
K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors
Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., & Pai, J.-K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14459 · Cited by 884
Protein Lipidation in Cell Signaling
Casey, P. J. (1995) · Science · doi:10.1126/science.7716512 · Cited by 774
Metadata
- Authors
- Kohl, N. E., Wilson, F. R., Mosser, S. D., Giuliani, E., deSolms, S. J., Conner, M. W., Anthony, N. J., Holtz, W. J., Gomez, R. P., & Lee, T. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1994-09-13
- Volume
- 91
- Issue
- 19
- Pages
- 9141-9145
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2107666634
- Cited by
- 285
- References
- 33
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.